| Item Type | Name |
|
Concept
|
Cisplatin
|
|
Academic Article
|
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer.
|
|
Academic Article
|
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
|
|
Academic Article
|
Cisplatin-based treatment of adrenocortical carcinoma.
|
|
Academic Article
|
Evaluation and treatment of testicular cancer.
|
|
Academic Article
|
Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509.
|
|
Academic Article
|
Management of cisplatin-induced delayed emesis.
|
|
Academic Article
|
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists.
|
|
Academic Article
|
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy.
|
|
Academic Article
|
Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
|
|
Academic Article
|
Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer.
|
|
Academic Article
|
Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
|
|
Academic Article
|
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
|
|
Academic Article
|
Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
|
|
Academic Article
|
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
|
|
Academic Article
|
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
|
|
Academic Article
|
A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
|
|
Academic Article
|
Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
|
|
Academic Article
|
Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin.
|
|
Academic Article
|
Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.
|
|
Academic Article
|
Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
|
|
Academic Article
|
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
|
|
Academic Article
|
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
|
|
Academic Article
|
Serotonin antagonists in the management of cisplatin-induced emesis.
|
|
Academic Article
|
Rationale for the use of a single fixed intravenous dolasetron dose for the prevention of cisplatin-induced nausea and vomiting. Pooled analysis of 14 clinical trials.
|
|
Academic Article
|
Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
|
|
Academic Article
|
Drug treatment of chemotherapy-induced delayed emesis.
|
|
Academic Article
|
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
|
|
Academic Article
|
Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
|
|
Academic Article
|
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
|
|
Academic Article
|
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
|
|
Academic Article
|
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
|
|
Academic Article
|
Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
|
|
Academic Article
|
Discordant human chorionic gonadotropin results giving rise to inappropriate therapy in a case of testicular cancer.
|
|
Academic Article
|
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
|
|
Academic Article
|
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Treatment of advanced non-small cell lung cancer with cisplatin, 5-fluorouracil, and mitomycin C.
|
|
Academic Article
|
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy.
|
|
Academic Article
|
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
|